Compare NBP & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBP | HELP |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | Canada |
| Employees | 30 | 50 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.8M | 214.5M |
| IPO Year | N/A | N/A |
| Metric | NBP | HELP |
|---|---|---|
| Price | $1.49 | $4.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $9.00 | ★ $51.50 |
| AVG Volume (30 Days) | ★ 646.2K | 615.1K |
| Earning Date | 04-07-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.46 | $3.76 |
| 52 Week High | $5.19 | $8.55 |
| Indicator | NBP | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 26.54 | 45.88 |
| Support Level | N/A | $4.22 |
| Resistance Level | $1.95 | $4.75 |
| Average True Range (ATR) | 0.12 | 0.26 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 6.19 | 58.08 |
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.